323581-36-8

Upstream product

• 134807-65-1 (S)-2-(((benzyloxy)carbonyl)amino)-3-methoxypropanoic acid 
• 1676-81-9 N-benzyloxycarbonyl-L-serine methyl ester 
• 84126-48-7 methyl N-[(benzyloxy)carbonyl]-O-methyl-L-serinate 

Downstream Products

• 1429777-62-7 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-methoxypropyl methanesulfonate 
• 1429777-61-6 benzyl [(2R)-1-amino-3-methoxypropan-2-yl]carbamate 
• 1446087-67-7 (S)-benzyl (1-methoxy-3-((trimethylsilyl)oxy)propan-2-yl)carbamate 
• 1446087-70-2 C₂₁H₂₇N₃O₉ 
• 1638689-34-5 C₁₅H₁₈N₄O₅ 
• 1638689-50-5 C₁₂H₁₆N₄O₃ 
• 1638689-47-0 C₁₂H₁₆INO₃ 
• 1446087-71-3 5'-O-DMT-2'-O-(N-benzyloxycarbonyl-2'-O-S-AMP)uridine 
• 1446087-69-9 C₂₁H₂₇N₃O₉ 

Relevant academic research and scientific papers

NOVEL 2'/3'/5'-(R/S)-SERINYL FUNCTIONALIZED OLIGONUCLEOTIDES

The present invention provides novel chiral serinyl functionalized tethered oligonucleotides i.e. R/S serinyl functionalized tethered oligonucleotides and the process of preparation thereof. Specifically, the present invention provides a modified nucleosi

Synthesis of Nα-Z protected amino alkyl triazole acids and their application to neo-glycopeptides synthesis

The synthesis of triazole linked glycopeptides employing 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) mediated coupling of Z-protected triazole acids with glycosyl amines and amino acid esters is described. The coupling proceeded smoothly at room temperat

Synthesis and properties of 2′-O-[R- and S-(2-amino-3-methoxy)propyl] (R-AMP and S-AMP) nucleic acids

Substitution at 2′-position by either amino- or methoxy-pendant groups of the antisense oligonucleotides (AONs) is known to enhance their therapeutic value. A simple modification is described here in which we introduce both these groups in the form of ena

3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS

The invention provides certain 3-pyridyl carboxamide-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.